After multiple decades of investigation, the precise mechanisms involved in fuel-stimulated insulin secretion are still being revealed. One avenue for gaining deeper knowledge is to apply emergent tools of "metabolomics," involving mass spectrometry and nuclear magnetic resonance-based profiling of islet cells in their fuel-stimulated compared with basal states. The current article summarizes recent insights gained from application of metabolomics tools to the specific process of glucose-stimulated insulin secretion, revealing 2 new mechanisms that may provide targets for improving insulin secretion in diabetes. . 7,8 However, it is unlikely that these cells completely mimic the glucose response mechanisms of normal human islets, and further engineering is likely to be required. In type 2 diabetes (T2D), the transition from the obese, insulin resistant, pre-diabetic state to full blown diabetes is triggered by β-cell failure, a general term that encompasses loss of normal nutrient signalling, an inability to maintain a high rate of insulin secretion to compensate for
| INTRODUCTION
The pancreatic islets of Langerhans play a critical role in metabolic physiology by translating key markers of nutritional status into hormonal changes that orchestrate systemic energy and substrate balance. The secretion of the primary hormonal mediators, insulin and glucagon, are regulated in a reciprocal fashion such that the anabolic hormone insulin is induced and secreted in the fed condition, whereas the catabolic hormone glucagon is preferentially released in the fasted state. A key signal of the fasted to fed transition is a rise in circulating glucose levels that triggers insulin secretion from islet β-cells. The mechanism of glucose-stimulated insulin secretion (GSIS) has been investigated for decades, and a canonical view of the process has emerged to broad acceptance. The central model holds that glucose induces insulin secretion via its own glycolytic and oxidative metabolism, leading to an increase in ATP:ADP ratio, inhibition of ATP-sensitive K + (K ATP ) channels, activation of voltage-gated Ca 2+ channels and influx of extracellular Ca 2+ to stimulate insulin granule exocytosis. 1 In more recent years, a modified version of the central model has emerged, in which the K ATP channel-dependent pathway is viewed as the primary mediator of the "triggering" or first phase of insulin secretion, whereas other signals are likely to be key drivers of the more prolonged "amplifying" or second phase of secretion. 2 Consistent with these ideas, several studies have showed a significant residual insulin secretion response to glucose in islets with pharmacologic or molecular suppression of K ATP channels, 2,3 strongly implicating K ATP -channel independent signalling mechanisms in mediating the complete response. Our laboratory and others have been focused on identifying the signalling pathways and mediators involved in the sustained second phase of insulin secretion. [4] [5] [6] In type 1 diabetes (T1D), β-cells are destroyed by the immune system, creating complete insulin deficiency. The long-practiced clinical intervention of insulin injection is life-saving, but can lead to hyperglycemic and hypoglycemic episodes due to the lack of regulation of insulin delivery by normal physiologic signals. Cell-based approaches to insulin replacement involving human islets or stem-cell derived β-cells have been actively investigated. Strategies for inducing differentiation of human stem cells to insulin-producing cells have advanced steadily, including recent reports of cells that exhibit some level of GSIS. 7, 8 However, it is unlikely that these cells completely mimic the glucose response mechanisms of normal human islets, and further engineering is likely to be required. In type 2 diabetes (T2D), the transition from the obese, insulin resistant, pre-diabetic state to full blown diabetes is triggered by β-cell failure, a general term that encompasses loss of normal nutrient signalling, an inability to maintain a high rate of insulin secretion to compensate for impaired insulin action, and eventual loss of β-cell mass. 9 A clearer understanding of the complete mechanism of GSIS is essential for ultimate success in creation of surrogate cells for insulin replacement therapy in T1D, as well as development of more efficacious drugs for treatment of T2D.
| METABOLOMICS TECHNOLOGY
The approach taken by our group to gain a deeper understanding of pancreatic islet cell nutrient signalling is to apply evolving tools of comprehensive metabolic analysis, or "metabolomics." With the advent of more sensitive mass spectrometers and accompanying chromatographic strategies, researchers are able to profile an increas- lines include an extraction protocol determined by statistical design prior to GC-MS analysis, 17 and an extraction procedure developed for adherent cells compatible with LC-MS. 18 In terms of analytical techniques, a 2D capillary LC-MS strategy has been devised to improve metabolite coverage in small tissue samples, 19 and direct matrix-assisted laser desorption/ionization (MALDI)-TOF analysis of single islets has also been reported. 20 More complete discussion of metabolomics methods and their use in disease research can be found in several recent reviews. 6, 12, [14] [15] [16] 21 Our laboratory has used a combination of NMR-and MS-based metabolic flux analysis coupled with targeted MS-based static profiling of key intermediates of glucose, lipid and amino acid metabolic pathways to gain insights into mechanisms of GSIS. Here we focus on our experiences in use of metabolomics for advancing our understanding of islet biology, and the implications of this new information for translational applications.
| METABOLIC FLUX ANALYSIS IMPLICATES ANAPLEROTIC METABOLISM OF GLUCOSE IN STIMULUS-SECRETION COUPLING
Our early work focused on subclones of the rat insulinoma cell line INS-1 with varying capacity for GSIS. 22 We reasoned that understanding of metabolic differences between robustly vs poorly glucose responsive cell lines might unveil novel metabolic pathways or factors that regulate glucose sensing. We first applied NMR-based mass isotopomer analysis to measure relative fluxes through the oxidative enzyme pyruvate dehydrogenase (PDH) and the anaplerotic enzyme pyruvate carboxylase (PC), using U-13 C glucose as substrate. The studies showed that variable GSIS across a panel of INS-1-derived cell lines was tightly correlated to pyruvate anaplerosis rather than pyruvate oxidation. 23 Flux through PC-catalyzed anaplerosis actually exceeds flux through PDH in isolated islets, 24 New mechanisms of glucose-stimulated insulin secretion revealed by metabolomics. In addition to the classical pathway involving glycolytic and oxidative metabolism of glucose to increase ATP:ADP ratio and inhibit K ATP channels, our recent metabolomics studies identify 2 pathways that play complementary roles. First, anaplerotic metabolism of glucose via pyruvate carboxylase (PC) rather than pyruvate dehydrogenase (PDH) creates excess tricarboxylic acid (TCA) cycle intermediates that leave mitochondria in the form of citrate and isocitrate via the citrate/isocitrate carrier (CIC). Isocitrate engages with the cytosolic, NADP-dependent isoform of isocitrate dehydrogenase (IDH1) to form NADPH and reduce glutathione, leading to reduction and activation of the deSUMOylase enzyme SENP1. In addition, metabolism of glucose via the pentose shunt enzymes glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) contributes to nucleotide synthesis, particularly the conversion of inosine monophosphate (IMP) to adenylosuccinate (S-AMP) via adenylosuccinate synthase (ADSS). S-AMP also stimulates insulin secretion in a SENP1-dependent manner. Figure modified from reference 6 and used with permission.
stimulation of exocytosis, 29, 30 an effect lost in mouse islets with transgenic deletion of SENP1 or human islets with shRNA-mediated suppression of SENP1 expression. 29 (see Figure 1 for overall schematic summary).
Do these findings have translational implications for rescue of GSIS in T2D? Importantly, the ability of glucose to drive insulin granule exocytosis in patch-clamped normal human β-cells is lost in β-cells from human donors with T2D. However, infusion of isocitrate or NAPDH rescues the exocytotic response in these cells. 29 These findings suggest that islets from humans with T2D may be defective at a step (or steps) of anaplerotic metabolism of glucose upstream of the IDH1 reaction. Further studies will be required to define the specific molecular lesions in anaplerotic metabolism of glucose in islets from T2D subjects.
| METABOLOMICS IDENTIFIES NOVEL NUCLEOTIDE SECRETAGOGUES
The classical K ATP -channel dependent pathway of GSIS invokes an increase in ATP:ADP ratio as a key signal for suppression of K ATP channel activity, leading to membrane depolarization, activation of voltage-gated Ca 2+ channels and triggering of insulin granule release by Ca 2+ signalling. However, recent non-targeted metabolomics studies suggested that glucose also alters the levels of a variety of other purine and nucleotide pathway intermediates in islet cells, [33] [34] [35] [36] although the functional significance of these changes was not defined. To investigate this further, our group developed a targeted, quantitative LC-MS/MS method for profiling of 37 different nucleotides and purine pathway intermediates. 37 The method was applied to the robustly glucose responsive INS-1-derived cell line 832/13 Also, analogous to the glucose/isocitrate pathway, the stimulatory effect of S-AMP on exocytosis in patch-clamped human β-cells is impaired by shRNA-mediated suppression of SENP1. 37 The new glucose/isocitrate and S-AMP pathways of GSIS summarized above are viewed as complementary to the classical K ATPchannel-dependent initiating pathway. It remains to be determined if the newly described pathways are additive or synergistic with each other and/or the K ATP channel-dependent mechanism in control of GSIS. Our studies on the glucose/isocitrate pathway also imply a particular impact of NADPH generated by the IDH1 reaction, relative to other NADPH producing enzymes such as malic enzyme or the pentose monophosphate shunt enzymes glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH).
With regard to the pentose pathway enzymes, inhibition of G6PDH with dehydroepiandrosterone (DHEA), 35 or 6PGDH by siRNA or the chemical inhibitor 6-AN, 38 were both reported to result in impaired GSIS. The effects of 6PGDH inhibition were ascribed to accumulation of early PPP intermediates and activation of p-ERK, 38 whereas DHEA treatment caused a decrease in GSH levels, although effects on NADPH were not reported. 35 These findings appear inconsistent with our findings that shRNA-mediated suppression of IDH1 is sufficient to ablate the glucose-induced increment in GSH and GSH:GSSG ratio in islet cells. 29 In addition, the finding that S-AMP has a direct effect to activate exocytosis in normal islets, and is able to rescue dysfunctional exocytosis in human T2D islets seems more aligned with the concept that S-AMP is the key regulator of GSIS produced by the pentose shunt. 37 However, these issues will require further investigation.
Future studies should include attempts to estimate the relative contributions of different pathways for NADPH formation, using recently described methods. 39 In this approach, pentose pathway flux is measured by the classical method of the difference between will add to our knowledge of key operative pathways for control of GSIS.
